In the KEYNOTE 811 study, the incorporation of pembrolizumab alongside trastuzumab and CTH as first-line therapy resulted in an impressive ORR of 74% in individuals diagnosed with HER-positive metastatic GC/GEJ. This evidence concerns the gene CTH and gastric cancer.